ELL and acute myeloid leukemia: Second, differentiation induction is a part of the antileukemic effect for several new/targeted anti-AML therapies, including FLT3 [52,53], isocitrate dehydrogenase (IDH) [54], bromodomain [55], lysine demethylase 1 (LSD1) [56], DOT1-like histone H3K79 methyltransferase (DOT1L) [57], exportin (XPOT) [58], menin (MEN) [59], and pyrimidine metabolism [60] inhibitors.